Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Payables (2016 - 2025)

Iovance Biotherapeutics has reported Payables over the past 13 years, most recently at $23.2 million for Q4 2025.

  • Quarterly results put Payables at $23.2 million for Q4 2025, down 15.81% from a year ago — trailing twelve months through Dec 2025 was $23.2 million (down 15.81% YoY), and the annual figure for FY2025 was $23.2 million, down 15.81%.
  • Payables for Q4 2025 was $23.2 million at Iovance Biotherapeutics, down from $32.2 million in the prior quarter.
  • Over the last five years, Payables for IOVA hit a ceiling of $33.1 million in Q4 2023 and a floor of $19.3 million in Q3 2023.
  • Median Payables over the past 3 years was $30.3 million (2023), compared with a mean of $28.6 million.
  • Biggest five-year swings in Payables: decreased 18.6% in 2024 and later rose 14.74% in 2025.
  • Iovance Biotherapeutics' Payables stood at $33.1 million in 2023, then fell by 16.95% to $27.5 million in 2024, then dropped by 15.81% to $23.2 million in 2025.
  • The last three reported values for Payables were $23.2 million (Q4 2025), $32.2 million (Q3 2025), and $33.0 million (Q2 2025) per Business Quant data.